Efficacy of intravenous lidocaine in improving post-operative nausea, vomiting and early recovery after laparoscopic gynaecological surgery

TAO WANG1*, HUI LIU2*, JIAN HONG SUN1, LIN WANG1 and JIAN YOU ZHANG1

Departments of 1Anesthesia and 2Endocrinology, Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China

Received August 21, 2018; Accepted February 28, 2019

DOI: 10.3892/etm.2019.7497

Abstract. Post-operative nausea and vomiting (PONV) is a major peri-operative complication. It has numerous adverse consequences that seriously affect the post-operative recovery of patients. The aim of the present study was to investigate the efficacy of intravenous lidocaine in improving PONV and recovery after laparoscopic gynaecological surgery. A total of 40 patients were randomly assigned to 2 groups: Group L (lidocaine group) and Group C (control group). The patients in Group L received intravenous lidocaine throughout the operation, while patients in Group C were given a saline infusion. Vital signs, recovery time, extubation time, dosage of remifentanil, first flatus time and defecation time of each patient were recorded. The incidence of PONV after surgery was also recorded. The recovery of the patients was evaluated by using the quality of recovery score (QoR-40). The total dose of remifentanil was significantly lower in Group L (P<0.05). However, the recovery time and extubation time were shorter in Group C (P<0.05). The first flatus time and defecation time were longer in Group C (P<0.05). The mean arterial pressure and heart rate in Group L were lower and more stable (P<0.05). At 6 h after surgery, the incidence of PONV was significantly lower in Group L vs. that in Group C (P<0.05). The QoR-40 score in Group C was significantly lower at 1 and 3 days after the operation compared with that in Group C (P<0.05). In conclusion, intravenous lidocaine administered to patients undergoing laparoscopic gynaecological surgery may reduce PONV and supports their early recovery [trial registration number in Chinese Clinical Trial Registry: ChiCTR-IOR-17010782 (March 5, 2017)].

Introduction

Rapid progress has been made in the development of minimally invasive surgery. Laparoscopic surgery has the advantages of less pain, more rapid recovery and less discomfort (1), and increasing numbers of patients are opting for this method. However, laparoscopic surgery is one of the high-risk surgical factors for post-operative nausea and vomiting (PONV) (2). A variety of studies have indicated that the incidence of PONV is ~30% after general anaesthesia and 50-70% after laparoscopic surgery (3,4). Females are more susceptible to PONV than males (5). An estimated 71-80% of patients suffer from PONV after general anaesthesia for gynaecological laparoscopy (6). Thus, PONV is one of the most common complaints after laparoscopic surgery together with post-operative pain. PONV is a distressing symptom after general anaesthesia and may increase patient discomfort and clinical problems, including disruption of the surgical wound, dehydration, electrolyte imbalance, aspiration pneumonia and haemorrhage (7,8). Furthermore, it may prolong recovery time, increase hospital costs and delay patient discharge (9). Therefore, reducing the incidence of PONV is conducive to the recovery of patients.

Numerous methods and drugs may prevent PONV, including 5-HT3 receptor antagonists, dopamine receptor antagonists, neurokinin-1 receptor antagonists, dexamethasone and propofol (10). However, these drugs are expensive or have numerous adverse effects. Peri-operative intravenous lidocaine is beneficial to the recovery of patients and has been widely used in clinical surgery (11). Clinical trials have indicated that intravenous lidocaine markedly reduces the incidence of PONV (12). Lidocaine has well-established analgesic, anti-hyperalgesic and anti-inflammatory characteristics (13). Certain studies have indicated that lidocaine accelerates the restoration of bowel function after surgery, which may be attributed to its anti-inflammatory effect. The favourable effects of lidocaine infusion include reduction of nausea and vomiting, pain scores, the duration of post-operative ileus and...
the duration of hospital stay according to a clinical trial on colon surgery (14). McKay et al (15) did not obtain the same positive results in a previous study regarding ambulatory surgery. In that study, lidocaine only reduced the consumption of narcotics and maintained a temporary reduction in pain scores (15). The reduction of post-operative opioid consumption and the anti-inflammatory properties of lidocaine may be involved in the improvement of opioid-induced bowel dysfunction, but the results of studies are contradictory, with certain studies supporting the hypothesis (16,17) while another does not (18). Another study demonstrated that intravenous lidocaine did not improve the opioid consumption or nausea and vomiting in patients who underwent open abdominal hysterectomy (19). However, the effect of pre-operative and intra-operative lidocaine infusion on PONV and quality of recovery in gynaecological laparoscopy surgery has remained to be investigated. Instead of the length of hospital stay, the quality of recovery score (QoR-40) (20) has become the most widely used measure of patient-assessed quality of recovery after surgery, as it is highly sensitive to clinical changes, valid, reliable, responsive and simple to use (21). In the present study, the effect of lidocaine infusion on nausea, vomiting and QoR-40 after gynaecological laparoscopic surgery was evaluated.

Materials and methods

Research subjects. The present study was approved by the ethics committee of the Affiliated Hospital of Yangzhou University (Yangzhou, China) and all patients provided written informed consent. According to a preliminary experiment, the required sample size was calculated and it was determined that a minimum of 20 patients were needed in each group (α error of 0.05 and β error of 0.2). Thus, a total of 40 patients aged 30-50 years with an American Society of Anaesthesiologists' physical status of I-II (22) who were scheduled for elective laparoscopic gynaecological surgery for ovarian and uterine disease were enrolled. All patients were randomly assigned to two groups, namely the lidocaine group (Group L: Age, 41.1±7.4 years) and the control group (Group C: Age, 40.6±8.3 years). Subjects were randomized with the aid of SPSS statistical analysis software (version 13; SPSS, Inc., Chicago, IL, USA) to receive one of two treatments in a double-blinded manner. The patients and anaesthesia providers were blinded with regard to the study group allocation throughout the study period. The solutions for injection/infusion were prepared by an independent researcher. The solution administered to Group L consisted of 1% lidocaine (China Resources Shuanghe Pharmaceutical Co., Ltd., Beijing, China) in coded 50-ml syringes, and the solution administered to Group C consisted of an equal volume of saline.

Inclusion and exclusion criteria. Patients with the following characteristics were excluded from the study: Cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, neurological disorders, acid-base balance electrolyte disorders, shock, pregnancy, history of tobacco use, history of PONV, pre-existing disorders of the gastrointestinal tract, use of anti-emetics within 48 h prior to surgery, chronic use of anti-cholinergic medication or chronic treatment with opioids, and an operation time of <30 min or >90 min. All operations were performed in the morning, were the first surgeries that day and followed a standardized procedure without additional procedures including irrigation, laparotomy and blood transfusion. Surgery and nursing were performed by the same team. All patients were enrolled between April and August 2017.

Anaesthesia method. Patients fasted after midnight the night prior to surgery, and 30 min prior to the induction of anaesthesia, they were orally pre-medicated with midazolam (0.04 mg/kg; Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou, China) and scopolamine (0.3 mg; Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., Guangzhou, China). Immediately prior to the induction of anaesthesia, the patients in Group L received an intravenous bolus injection of 1.5 mg/kg lidocaine. In Group L, the lidocaine infusion was continued at a rate of 2 mg/kg/h throughout the operation, and patients were transferred to the post-anaesthesia care unit after surgery. The patients in the control group were given a saline infusion administered in a similar manner. Prior to the induction of anaesthesia, the patients' electrocardiogram, heart rate, and oxygen saturation were monitored continuously, and non-invasive arterial blood pressure was recorded at 5-min intervals throughout the procedure. For anaesthetic induction, 2 mg/kg propofol (AstraZeneca UK Limited, London, UK) and 4 µg/kg fentanyl (Yichang Renfu Pharmaceutical Co., Ltd., Yichang, China) were intravenously administered prior to tracheal intubation. In each of the two groups, tracheal intubation was facilitated with 0.2 mg/kg cis-attracurium (Jiangsu Hengrui Pharmaceutical Co., Ltd., Lianyungang, China), and cis-attracurium was also used for intra-operative muscle relaxation in all patients. Full muscle relaxation was maintained during surgery. Anaesthesia was maintained with 70-90 µg/kg/min propofol and 0.2-0.5 µg/kg/min remifentanil (Yichang Renfu Pharmaceutical Co., Ltd.). During surgery, maintenance doses of anaesthetics were adjusted to maintain bispectral index (BIS) within 40-60 in each group. Lactated Ringer's solution (8 ml/kg/h; China Resources Shuanghe Pharmaceutical Co., Ltd.) was infused throughout the surgery.

Record indicator. Mean arterial pressure, heart rate and oxygen saturation were recorded prior to the operation, at the time of intubation, during pneumoperitoneum, at the time of extubation, at 1 min after extubation and at 5 min after extubation. The anaesthesia time, operating time, pneumoperitoneum time, recovery time, extubation time, dosage of remifentanil, first flatus time, defecation time and length of hospital stay were recorded for each patient. The Ramsay sedation scale (RSS) score (23) was recorded at 1 min, 5 min and 30 min after extubation.

The incidence of PONV, the nausea score and the use of anti-emetics at 1, 6 and 24 h after surgery were also recorded. Pain scores were assessed using the visual analogue scale (VAS) (24) every 6 h until 48 h after the operation. The recovery of the patients was evaluated by using the QoR-40 at 1 day prior to the operation and at 1, 3 and 5 days after the operation.

According Eberhart et al (25), the severity of PONV during the 24 h after surgery was divided into four categories: None
(absence of nausea and vomiting), mild (the patient suffered only mild nausea), moderate (the patient suffered 1-2 emetic episodes or moderate or severe nausea without exogenous stimulus and anti-emetics were required), and severe (the patient vomited at least once or experienced nausea at least twice, and anti-emetics were required at least once).

The QoR‑40 contains 40 items measuring five aspects of patient recovery: Psychological support (7 items), physical comfort (12 items), emotional wellbeing (9 items), physical independence (5 items) and pain (7 items) (17). Each item is divided into five levels (for positive items: 1, none of the time; 2, some of the time; 3, often; 4, most of the time; and 5; all of the time. For negative items, the scoring was reversed). The individual scores are then added up and the resulting QoR‑40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery), with a higher QoR‑40 score indicating a better recovery.

At 1 day prior to surgery, the QoR‑40 instrument was explained to the patients. After they understood the meaning of the questionnaire, the QoR‑40 scores were evaluated and recorded as the pre‑operative baseline health status at day 0 (D0) by the assigned medical professional. QoR‑40 scores were also recorded at the same time of day at 1 day post‑surgery (D1), D3 and D5 by the assigned medical professional.

Statistical analysis. The major results are expressed as the mean ± standard deviation, the median (range) or the number of patients. Student’s t‑test was used to compare continuous variables between the groups. The \( \chi^2 \) test or Fisher’s exact test was used for categorical variables. Statistical analysis was performed using SPSS 13.0 for Windows (SPSS, Inc.).

**Results**

**General information.** A total of 45 patients were initially recruited to the current study, but 5 patients were excluded. The remaining 40 patients were subsequently allocated to the two equally sized groups and completed the study. The data from these patients were used in the analysis. No significant differences were observed between the two groups in terms of age, body weight or body height. Intraoperative data, including the duration, the CO\( _2 \) pressure, the length of anaesthesia and pneumoperitoneum were similar between the two groups (Table I).

**Peri‑operative remifentanil dose, mean arterial pressure and heart rate are lower in the lidocaine group.** The total dose of remifentanil administered peri‑operatively to patients in the lidocaine group was significantly lower than that given to the saline group: 472.5±134.2 µg (saline) vs. 167.5±94.9 µg (P<0.001). Despite the decreased use of remifentanil, the mean arterial pressure and heart rate at the time‑points T1‑T5 were lower in the lidocaine group than those in the saline group (Figs. 1 and 2).

**Patients in Group C recover quickly compared with those in Group L.** The recovery and extubation times were shorter in Group C than they were in Group L (Table II). The first flatus time (1,752±342 min) and the defecation time (1,972±363 min) in Group C were longer than those in Group L (1,452±273 and 1,664±353 min, respectively), but the length of the hospital stay was not significantly shorter in Group L (P=0.32; Table II).
4726 WANG et al. INTRAVENOUS LIDOCAINE IMPROVES POST-OPERATIVE NAUSEA, VOMITING AND RECOVERY

PONV incidence is similar in the two groups. There were no significant differences in the incidence of PONV between the groups at 1 and 24 h after surgery; however, the incidence of PONV was significantly lower at 6 h after surgery in Group L compared with that in Group C. The severity of PONV was not significantly different between the groups at any given time-point. Compared to Group C, fewer anti-emetic agents were used in Group L (Table III).

Patients in Group C have a faster recovery time compared with those in Group L. The VAS scores in Group L were lower compared with those in Group C at 18, 24, 30 and 36 h after the operation. The RSS score was not significantly different between the groups at any time-point after extubation (Figs. 3 and 4). The QoR-40 scores of Group C were significantly lower compared with those of Group L at 1 and 3 days after the operation. No significant difference was observed at 5 days (Table IV).

Discussion

PONV more frequently occurs in cases with the presence of peri-operative haemodynamic instability and in female patients, non-smokers and patients with past histories of PONV or motion sickness (5). General anaesthesia with inhalational anaesthetics or nitrous oxide with the peri-operative use of opioids may increase nausea and vomiting (26). Laparoscopic gynaecological surgery is more likely to cause PONV (2), which led to the choice of this type of surgery for the present study. According to a previous study, there was no significant difference in the incidence of PONV when the duration of

Table II. Peri-operative parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group C (n=20)</th>
<th>Group L (n=20)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recovery time (min)</td>
<td>7.4±4.3</td>
<td>11.7±4.9</td>
<td>0.005</td>
</tr>
<tr>
<td>Extubation time (min)</td>
<td>12.1±3.8</td>
<td>16.8±3.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peri-operative remifentanil usage (µg)</td>
<td>472.5±134.2</td>
<td>167.5±94.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>First flatus time (min)</td>
<td>1,752±342</td>
<td>1,452±273</td>
<td>0.004</td>
</tr>
<tr>
<td>Defecation time (min)</td>
<td>1,972±363</td>
<td>1,664±353</td>
<td>0.009</td>
</tr>
<tr>
<td>Discharge time (days)</td>
<td>7.2±1.8</td>
<td>6.7±1.3</td>
<td>0.325</td>
</tr>
</tbody>
</table>

Values are expressed as the mean ± standard deviation. There were no significant differences between the groups. L, lidocaine; C, control.

Table III. Details regarding PONV.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group C (n=20)</th>
<th>Group L (n=20)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with symptoms of PONV at specific time-points (h)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>7 (35)</td>
<td>4 (20)</td>
<td>0.288</td>
</tr>
<tr>
<td>6</td>
<td>10 (50)</td>
<td>4 (20)</td>
<td>0.047</td>
</tr>
<tr>
<td>24</td>
<td>2 (10)</td>
<td>1 (5)</td>
<td>0.999</td>
</tr>
<tr>
<td>Nausea (none/mild/moderate/severe) at specific time-points (h)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>13/5/2/0</td>
<td>16/3/1/0</td>
<td>0.288</td>
</tr>
<tr>
<td>6</td>
<td>10/6/3/1</td>
<td>16/3/1/0</td>
<td>0.047</td>
</tr>
<tr>
<td>24</td>
<td>18/2/0/0</td>
<td>19/1/0/0</td>
<td>0.999</td>
</tr>
<tr>
<td>Anti-emetics usage (%)</td>
<td>8 (40)</td>
<td>3 (15)</td>
<td>0.077</td>
</tr>
</tbody>
</table>

Values are expressed as n (%). L, lidocaine; C, control; PONV, post-operative nausea and vomiting.

Table IV. Quality of recovery score in the two groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group C (n=20)</th>
<th>Group L (n=20)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 day prior to operation</td>
<td>191.2±3.8</td>
<td>191.4±3.4</td>
<td>0.862</td>
</tr>
<tr>
<td>1 day post-operatively</td>
<td>166.3±8.2</td>
<td>173.0±9.8</td>
<td>0.025</td>
</tr>
<tr>
<td>3 days post-operatively</td>
<td>179.5±5.9</td>
<td>183.3±6.5</td>
<td>0.046</td>
</tr>
<tr>
<td>5 days post-operatively</td>
<td>189.2±4.3</td>
<td>189.3±5.6</td>
<td>0.949</td>
</tr>
</tbody>
</table>

Values are expressed as the mean ± standard deviation. L, lidocaine; C, control.
Lidocaine is a commonly used local anaesthetic and anti-arrhythmic drug. It reversibly inhibits the generation and propagation of action potentials by blocking sodium currents, resulting in sedative and antalgic effects (28).

A study by Kabasal et al. (16) indicated that the induction of anaesthesia with an intravenous administration of 1.5 mg/kg lidocaine and the maintenance of anaesthesia with 2.0 mg/kg/h lidocaine until the end of the surgery result in plasma concentrations of lidocaine reaching 2.4±0.6 µg/ml, which is effective for pain control. It is lower than the toxic plasma concentration of lidocaine (5 µg/ml) (29). Therefore, the manner of administration of lidocaine in the present study was safe.

The present study indicated that the use of opioids in the lidocaine group was less than that in the control group, consistent with the results of a previous study (30). Intravenous lidocaine may inhibit the discharge of neurons and fibres by blocking sodium channels (31) and reduce the threshold of peripheral noxious stimulation to achieve analgesic and pain desensitization effects (32). In addition, intravenous lidocaine may inhibit G protein-coupled receptors, N-methyl-D-aspartate receptors, the release of inflammatory factors and the function of leukocytes. Therefore, it has anti-inflammatory, analgesic, anti-hyperalgesic and immune regulatory effects (33-36).

A previous study indicated that the major mechanism of the anaesthetic action of propofol is the inhibition of sodium channels in the central nervous system, and lidocaine is able to enhance the effect of propofol by also inhibiting sodium channels (37). The present study indicated that the blood pressure and heart rate were lower but more consistent in the lidocaine group than they were in the control group at all time-points. Although the recovery and extubation times were longer in the lidocaine group than those in the control group, the RSS score was not significantly different between the two groups after extubation. A probable reason for this was that the patients in the lidocaine group were more tolerant to catheter stimulation, but it did not affect the sobriety after extubation. The hemodynamics of the patients in the lidocaine group were more consistent at the time of extubation and during the recovery period, and the patients also felt more comfortable. This may be due to the sedative, analgesic and stress-reducing effects of lidocaine (29,38).

The half-life of lidocaine is 1.5-2.0 h with continuous intravenous infusion. A previous study by Koppe et al. (39) indicated that the analgesic effect of intravenous lidocaine lasted for almost 72 h after the surgery. The present study indicated that continuous infusion of lidocaine is able to significantly relieve post-operative pain, and the greatest difference in pain was observed between 12 and 42 h after surgery. This may occur due to the pain of endoscopic surgery being relatively less than that associated with invasive surgery, and the greatest pain had passed at 2 days after the surgery. In addition, most patients refused to endure the acute pain and requested post-operative analgesia in the preliminary experiment. In order to enhance the comfort level of patients and reduce doctor-patient disputes, patients in two groups were intravenously given flurbiprofen axetil (1 mg/kg) for post-operative analgesia at the end of the operation (40). The half-life of flurbiprofen axetil is ~5.8 h (41), and therefore, the pain within the first 6 h after the operation was not evaluated. This is also a shortcoming of the present study. Therefore, it is necessary to further investigate the analgesic effect of lidocaine on the acute pain period within 6 h after surgery.

The damage of intestinal function after surgery is associated with post-operative systemic inflammatory responses. A previous study by Kuo et al. (42) indicated that intravenous lidocaine may reduce pro-inflammatory factors and is beneficial to the recovery of intestinal function. Furthermore, stimuli including intra-operative traction and pneumoperitoneal pressure may activate the intestinal nerve plexus, leading to injury of intestinal function. Intravenous lidocaine may excite the intestinal smooth muscle by blocking the mesenteric plexus and is beneficial to the recovery of intestinal function (14). In the present study, the first flatus and defecation times were earlier in the lidocaine group than they were in the control group, indicating that lidocaine is helpful in the early recovery of intestinal function.

The results of the present study suggested that the incidence of PONV was significantly lower in the lidocaine group than that in the control group, and the severity of PONV was also significantly reduced. This may be due to the following factors: Improvement of the senses of patients during the recovery period from anaesthesia, reduction of the use of opioid agents, maintenance of haemodynamic stability during the peri-operative stage, reduction of post-operative pain and promotion of the early recovery of the gastrointestinal tract. However, the mechanism by which lidocaine prevents PONV remains elusive.

QOR40 is an effective, reliable and simple scale used to evaluate the quality of the post-operative recovery of patients. It has been successfully used to assess the quality of post-operative recovery in different patients and after different types of surgery, including heart surgery, laparoscopic gall-bladder surgery and joint replacement surgery (43-45). The present study indicated that the recovery quality was much better in the lidocaine group than that in the control group at 1 and 3 days after surgery. However, the recovery quality was not significantly different between the groups at 5 days after surgery. Therefore, intravenous lidocaine may accelerate the early recovery of patients undergoing endoscopic gynaecological surgery. This promotion of early recovery may be associated with the beneficial effects of lidocaine mentioned above. However, the definite duration and efficiency of the promotion of post-operative recovery by lidocaine remain elusive. In addition, in the present study, patients with small surgical trauma, short operation times and good general health were selected. Therefore, further studies are required to determine whether lidocaine has the same effect on patients with comparatively greater surgical trauma, longer operation times and poor general health.

In conclusion, intravenous lidocaine used in patients undergoing laparoscopic gynaecological surgery may safely and effectively prevent PONV, and it may promote patients' early recovery, thus making it worthwhile to increase the use of lidocaine in the clinical setting.
References


34. Sugimoto M, Uchida I and Mashimo T: Local anaesthetics have different mechanisms and sites of action at the recombinant N-methyl-D aspartate (NMDA) receptors. Br J Pharmacol 138: 876‑882, 2003.


